Daxor Corporation (DXR)

Currency in USD
11.95
-0.17(-1.40%)
Closed·
11.850.00(0.00%)
·
DXR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.9212.26
52 wk Range
7.1014.76
Key Statistics
Prev. Close
11.95
Open
11.92
Day's Range
11.92-12.26
52 wk Range
7.1-14.76
Volume
5.25K
Average Volume (3m)
5.09K
1-Year Change
59.3333%
Book Value / Share
7.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.50
Upside
+88.28%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Daxor Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Daxor Corporation Company Profile

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

Sector
Financial
Employees
45

Daxor Corporation Earnings Call Summary for Q4/2024

  • Revenue surged 116.5% year-over-year in Q4 2024; company achieved cash flow breakeven in Q1 2025
  • Stock price rose 3.6% post-announcement; analysts set $24.75 price target, suggesting significant upside potential
  • Developing next-generation blood volume analyzer; plans to resubmit for FDA approval and file for CLIA waiver in 2025
  • Expanded market presence with new accounts and increased kit sales; less than 1% of potential market currently reached
  • Transitioning from 1940 Act to 1934 Act company designation to enhance market positioning
Last Updated: 2025-03-06, 05:08 p/m
Read Full Transcript

Compare DXR to Peers and Sector

Metrics to compare
DXR
Peers
Sector
Relationship
P/E Ratio
38.7x−6.9x−0.6x
PEG Ratio
11.36−0.050.00
Price/Book
2.0x3.5x2.6x
Price / LTM Sales
1,050.2x3.4x3.3x
Upside (Analyst Target)
85.6%34.9%44.5%
Fair Value Upside
Unlock−7.3%5.2%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.50
(+88.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lake Street Capital Markets
Buy23.00+92.47%-New CoverageFeb 11, 2026
Ascendiant Capital
Buy25.00+109.21%24.75MaintainMar 17, 2025

Earnings

Latest Release
Aug 29, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
18.35K / --
EPS Revisions
Last 90 days

DXR Income Statement

FAQ

What Is the Daxor (DXR) Stock Price Today?

The Daxor stock price today is 11.95 USD.

What Stock Exchange Does Daxor Trade On?

Daxor is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Daxor?

The stock symbol for Daxor is "DXR."

What Is the Daxor Market Cap?

As of today, Daxor market cap is 69.64M USD.

What Is Daxor's Earnings Per Share (TTM)?

The Daxor EPS (TTM) is 0.36.

From a Technical Analysis Perspective, Is DXR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Daxor Stock Split?

Daxor has split 0 times.

How Many Employees Does Daxor Have?

Daxor has 45 employees.

What is the current trading status of Daxor (DXR)?

As of Feb 27, 2026, Daxor (DXR) is trading at a price of 11.95 USD, with a previous close of 11.95 USD. The stock has fluctuated within a day range of 11.92 USD to 12.26 USD, while its 52-week range spans from 7.10 USD to 14.76 USD.

What Is Daxor (DXR) Price Target According to Analysts?

The average 12-month price target for Daxor is 22.50 USD, with a high estimate of 23 USD and a low estimate of 22 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +88.28% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.